Title: Immuno-proteomic profiling reveals abundant airway CD8 T cells and ongoing

epithelial injury in prolonged post-COVD19 respiratory disease

Authors: Bavithra Vijayakumar[1,2,3,+], Karim Boustani[1,4,+], Patricia P. Ogger[1,+], Artermis

Papadaki[5,+], James Tonkin[1,3], Christopher M. Orton[1,3], Poonam Ghai[1], Kornelija

Suveizdyte[1], Richard J. Hewitt[1,3], Robert J. Snelgrove[1,4], Philip L. Molyneaux[1,3],

Justin L. Garner[2,3], James E. Peters[5,*], Pallav L. Shah[1,2,3,*], Clare M. Lloyd[1,4*] and

James A. Harker[1,4,*]

[1]National Heart and Lung Institute, Imperial College London, London, UK

[2]Chelsea and Westminster Hospital, London, UK

[3]Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation

Trust, London, UK

[4]Asthma UK Centre for Allergic Mechanisms of Asthma

[5]Centre for Inflammatory Disease, Dept of Immunology and Inflammation, Imperial

College London, Hammersmith Hospital, London, UK

[+]denotes equal contribution

*co-senior authors

Lead contact: Dr James A Harker, j.harker@imperial.ac.uk

Sir Alexander Fleming Building, National Heart and Lung Institute, South Kensington

Campus, Imperial College London, London, UK. SW7 2AZ.

Highlights

• The post-COVID19 airway is characterized by increased cytotoxic lymphocytes.

• Distinct airway proteomes are associated with the airway immune cell landscape.

• The peripheral blood does not predict immune-proteome alterations in the airway

post-COVID19.

• Persistent abnormalities in the airway immune-proteome post-COVID19 airways

correlate with ongoing epithelial damage.

Summary

Some patients hospitalized with acute COVID19 suffer respiratory symptoms that

persist for many months. To characterize the local and systemic immune responses

associated with this form of 'Long COVID', we delineated the immune and proteomic

landscape in the airway and peripheral blood of normal volunteers and patients from

3 to 6 months after hospital discharge. The bronchoalveolar lavage (but not

peripheral blood) proteome was abnormal in patients with post-COVID19 lung

disease with significantly elevated concentration of proteins associated with

apoptosis, tissue repair and epithelial injury. This correlated with an increase in

cytotoxic lymphocytes (especially tissue resident CD8$^+$ T cells), lactate

dehydrogenase and albumin (biomarkers of cell death and barrier integrity). Follow-

up of a subset of these patients greater than 1-year post-COVID19 indicated these

abnormalities resolved over time. Collectively, these data indicate that COVID-19

results in a prolonged change to the airway immune landscape in those with

persistent lung disease, with evidence of cell death and tissue repair linked to

ongoing activation of cytotoxic T cells.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) related coronavirus

disease (COVID19) manifests as a spectrum of acute illnesses ranging from mild

respiratory symptoms to severe, sometimes fatal, respiratory failure (Docherty et al.,

2020). While the acute impact of COVID19 on morbidity and mortality is well-

documented, we are still in the infancy of understanding the longer-term

consequences. Morbidity from a range of persistent symptoms, including

breathlessness, fatigue and memory impairment have been noted in patients

recovering after the acute illness and described under the umbrella term of "long

COVID" (Nalbandian et al., 2021; Sigfrid et al., 2021). Complex respiratory

complications have been found in up to 18.4% of inpatients (Drake et al., 2021), and

persistent breathlessness reported in more than 50% of patients recovering from

COVID19 (Mandal et al., 2021). The underlying aetiology for persistent respiratory

morbidity is likely to be multifactorial but may be due to persistent parenchymal

abnormalities and resultant ineffective gaseous exchange. Persistent radiological

abnormalities post-COVID19 are common and may be present even up to 6 months

post hospital discharge (Fabbri et al., 2021; Guler et al., 2021; Han et al., 2021; Myall

et al., 2021). There is, therefore, a pressing need to understand the molecular and

cellular basis of post-COVID19 pulmonary syndromes.

The acute immunological and inflammatory events that occur during human

respiratory virus infections, including SARS-CoV-2, are relatively well described

(Harker and Lloyd, 2021). In contrast, the immunological landscape of the human

respiratory tract after recovery from acute viral infection is poorly understood. SARS-

CoV-2 infection results in formation of long-lasting systemic immunological memory,

with virus-specific antibodies and T cell responses still detectable in the majority of

those infected at least 8 months post infection and higher titers seen in previously

hospitalized individuals (Dan et al., 2021). Circulating lymphocyte counts and the

function and frequency of monocytes are also reduced during acute disease, but they

appear to return to normal shortly after resolution of acute disease (Mann et al.,

2020; Scott et al., 2020). Likewise, plasma concentrations of inflammatory mediators

such as IL-6 and CXCL10, that are highly elevated in acute disease, reduce as

individuals recover (Rodriguez et al., 2020). Together, this suggests that systemic

inflammatory and immune responses associated with acute disease severity resolve

in line with recovery from the acute symptoms. It therefore remains unclear if the

severity of inflammation during acute disease is associated with the persistent

respiratory pathology seen in some SARS-CoV-2 infected individuals months after

infection, or if there is ongoing inflammation in these individuals.

This study sought to examine the relationship between the immune system and

respiratory pathology post-COVID19. The immune cell and proteomic composition of

the airways and peripheral blood were analyzed in a group of previously hospitalized

COVID19 patients with persistent radiological abnormalities in their lungs over 3

months post discharge. In comparison to healthy individuals, the post-COVID19

airway showed substantial increases in activated tissue resident memory CD8$^+$ and

CD4$^+$ TRM, and an altered monocyte pool. The airway proteome was also distinct

from that observed in healthy individuals, with elevation in proteins associated with

ongoing cell death, loss of barrier integrity and immune cell recruitment. Importantly,

none of these alterations were predicted by changes in the proteome or immune cells

of the matched peripheral blood. Moreover, the scale of these alterations was not

linked to the initial severity of disease while in hospital but instead was heterogenous.

Some individuals displaying heightened T cell responses associated with significant

increases in CXCR3 chemokines in the airways and linked to prolonged epithelial

damage and extracellular matrix (ECM) dysregulation, while other individuals

exhibited a return to relative airway homeostasis. Subsequent long-term follow-up

also suggested that these ongoing changes to the airway landscape progressively

return to normal.

Results

Increased airway lymphocyte numbers characterize patients recovering from
hospitalization with SARS-CoV-2

We recruited 38 patients undergoing bronchoscopy for investigation of persistent
respiratory abnormalities 3-6 months following infection after acute SARS-CoV-2
infection (post-COVID19) (**Figure 1A).** All patients had both ongoing respiratory
symptoms and radiological pulmonary abnormalities on computed tomography (CT)
scanning. We obtained plasma samples from peripheral blood and bronchoalveolar
lavage (BAL) fluid from their airways. We stratified the post-COVID19 cohort based
on the level of respiratory support used during their initial hospitalization with acute
COVID19, into moderate (no or minimal oxygen administered), severe (non-invasive
ventilation) and very severe (invasive ventilation). To provide a control group, we
used BAL and plasma samples obtained from 10 healthy volunteers recruited prior to
the COVID19 pandemic (demographic information in **Table S1**).

We first compared the cellular composition of BAL fluid in post-COVID19 patients to
healthy controls (HC) by flow cytometry. Post-COVID19 patients had a significantly
higher numbers of cells in their airways compared to the healthy volunteers (**Figure**
1B). This increased cellularity was due to significantly elevated numbers of airway T
and B cells, and a trend towards increased airway macrophages (AM), $CD56^+CD3^-$
(natural killer, NK) cell and $CD56^+CD3^+$ (NKT) cell numbers, while $CD14^+$ monocyte,
eosinophil and neutrophil numbers were similar to those found in healthy controls
(**Figure 1C**). As a proportion of airway leukocytes, $CD14^+$ monocytes and neutrophils
were decreased in patients recovering from COVID19 compared to healthy controls
(**Figure S1A**). There was no association between the severity of acute COVID19 in
hospital and the immune cell composition of the post-COVID19 airways (**Figure 1C**).
In contrast to the peripheral lymphopenia that is associated with acute COVID19
(Chen and Wherry, 2020), we found that in this post-COVID19 patient cohort the
frequency of T cells, B cells and $CD14^+$ monocytes in the peripheral blood was
broadly similar to healthy controls (**Figure S1B**), although the proportion of NK and
NKT cells was significantly decreased (**Figure S1B**). Collectively, these data indicate
that after recovery from severe SARS-CoV-2 infection, immune cell frequencies in
the peripheral blood are comparable to those in a group of age-matched controls. In
contrast, the immune landscape of the airways remains altered, being marked by
residual lymphocytes.

The post-COVID19 airway immune landscape displays a limited relationship to
inflammatory biomarkers found during acute disease

Severe COVID19 has a distinctive clinical biomarker blood profile, characterized by
elevated inflammatory markers (including C-reactive protein (CRP) and ferritin),
elevated coagulation markers (D-dimer and fibrinogen), and lymphopenia (Guan et
al., 2020). At the time of hospitalization, our patients displayed a similar pattern of
clinical laboratory test abnormalities (**Table S1)**. We therefore examined whether
there was any association between the peak levels (or nadir in the case of
lymphocyte count) of these clinical biomarkers measured during acute hospitalization
and the immune cell composition of the airways at 3 months following discharge. Of
the 5 biomarkers measured, ferritin correlated (Spearman rho > 0.4) with total airway
monocytes, specifically classical and intermediate monocytes, and eosinophils, and
inversely correlated with AM (**Table S2**). Total airway B cells correlated with peak D-
dimer, while airway eosinophils correlated with lowest lymphocytes. None of the
biomarkers correlated with follow up airway T cell, NK cell or neutrophil numbers, and
fibrinogen and WCC showed no substantial correlation with any airway immune cell
analyzed. Taken together these data suggest that the post-COVID19 airway immune
cell composition shows a limited relationship with the severity of initial acute disease.
This observation is supported by the lack of differences in immune cell composition
when segregating between moderate, severe and very severe patients (**Figure 1**).

The post-COVID19 airway displays a proteome profile distinct from that found in the
circulation.

Since clinical biomarkers did not reveal a relationship between acute disease and
prolonged pathology and immune responses in the lungs post discharge, we next
evaluated the airway and blood (plasma) proteomes at follow-up. We used the Olink
proteomics platform to measure 435 unique proteins (**Supplementary File 1A**) in 19
post-COVID19 patients and 9 healthy volunteers. The proteins measured were highly
enriched for those involved in immuno-inflammatory processes (**Supplementary File**
1B-C).

Principal components analysis (PCA) of BAL fluid proteomes revealed differences
between post-COVID19 patient and healthy control samples (**Figure 2A**), with
separation of case and controls most evident along PC1. In plasma, PCA also

revealed differences in post-COVID19 patients and healthy controls, most evident

along PC2, although the differences appeared less marked than for BAL. However, in

both BAL and plasma there was considerable overlap in the spatial location of post-

COVID19 and healthy control samples in the PCA plots. Unsupervised hierarchical

clustering revealed two major clusters of samples in BAL, one consisting

predominantly of post-COVID19 samples and the other predominantly healthy

controls (**Figure S2A**), although, as with the PCA, some patient and control samples

were grouped together. In contrast, in plasma, there was no visible structure to the

clustering and lack of clear separation of cases and control samples (**Figure S2B**).

These analyses indicate that post-COVID19 syndromes are reflected to a much

greater extent in the airway proteome than the peripheral blood. They also suggest

that there is considerable heterogeneity in the BAL and blood proteomes of post-

COVID19 patients, with some patients displaying similar profiles to that of healthy

controls, despite persistent symptoms and radiological findings.

We next performed differential protein abundance analysis comparing post-COVID19

cases with healthy controls. In BAL fluid, we identified 22 proteins with significantly

altered concentration (5% false discovery rate, FDR) (**Figure 2B-C**, **Supplemental**

File 1D). These were all upregulated in post-COVID19 patients compared to healthy

controls (**Figure 2C**). In order to provide a succinct and standardised nomenclature,

we report proteins by the symbols of the genes encoding them (see **Supplementary**

File 1A for a mapping of symbols to full protein names). The proteins that were most

significantly differentially abundant between post-COVID19 patients and healthy

controls were: SERPINA7 (thyroxine binding globulin), DPP4 (dipeptidyl peptidase 4),

SERPINA5 (plasma serine protease inhibitor), KLK6 (kallikrein related peptidase-6),

LYVE1 (Lymphatic vessel endothelial hyaluronic acid receptor 1), AREG

(amphiregulin), F3 (factor 3), FLT3LG (Fms-related tyrosine kinase 3 ligand), QPCT

(glutaminyl-peptide cyclotransferase), and SRC (Proto-oncogene tyrosine-protein

kinase Src) (**Figure 2C-D**). Pathway annotation of the 22 upregulated proteins using

String-DB highlighted "leucocyte activation", "regulation of cell death", "response to

injury" and "response to wounding" (**Supplemental File 1E).** Next, we analyzed the

relationship between the 22 differentially abundant proteins and the airway immune

cell proportions. Neutrophils most strongly correlated with AREG and LDLR (low

density lipoprotein receptor), while monocyte proportions correlated with F3,

FLT3LG, MB (myoglobin) and IL1RN (IL-1 receptor antagonist protein) (**Figure 2E**).

T cells, despite being significantly elevated in the airways of post-COVID19 patients,

displayed only weak correlations with the differentially abundant proteins.

In contrast to BAL, no significant differences between protein levels were detected in

plasma in post-COVID19 patients versus healthy controls (**Supplemental File 1F**).

Comparison of the estimated $\log_2$ fold changes for the 22 proteins upregulated in

post-COVID19 BAL fluid with the estimated $\log_2$ fold changes for these same

proteins in plasma revealed no correlation (**Figure S2C-D**), indicating an absence of

any relationship between airway and plasma proteome changes.

The modest sample size and multiple testing burden of 435 proteins likely limited the

statistical power to detect differentially abundant proteins. To examine whether there

was evidence of signal in the proteomic data that was hidden by the hard-

thresholding in the differential abundance analysis, we examined quantile-quantile

(QQ) plots of the distribution of expected p-values under the null hypothesis of no

proteomic differences between cases and controls versus the observed p-values. For

both BAL and plasma, the QQ plots revealed substantial deviation from the diagonal

(albeit more so in BAL), indicating the presence of systematic differences between

post-COVID19 and healthy controls for plasma proteins as well as BAL proteins

(**Figure S3A**). Corroborating this, the distribution of p-values for the proteins was not

uniformly distributed, with skewing towards zero (**Figure S3B**). This is consistent with

the observation that there was separation of post-COVID19 and control samples on

the PCA plots for both BAL and plasma. In summary, these data suggests that there

are differences in both the BAL and plasma proteomes of post-COVID19 cases

compared to healthy controls, but that the effects are much stronger in BAL and this

study was underpowered to detect them in plasma.

To increase power, and investigate potential protein-protein relationships, we utilized

a network analysis method, Weighted Coexpression Network Analysis (WGCNA)

(Langfelder and Horvath, 2008; Zhang and Horvath, 2005), that leverages the

correlation between proteins to enable dimensionality reduction and thus reduce

multiple testing burden. We used WGCNA to identify modules of correlated proteins,

and then tested for association between these protein modules (represented

quantitatively by an eigenprotein value) and case/control status. In BAL fluid, this

revealed two modules ('red' and 'blue') associated with case/control status using a

5% FDR significance cut-off (**Figure 3A, Supplementary File 1G-I**). Applying a more

conservative Bonferroni corrected p-value threshold, only the red module remained

significant ($P_{Bonferonni}$ 0.03).

The red module consisted of 37 proteins (**Figure 3B, Supplementary File 1H**).

Overall, the red module was characterized by proteins associated with chemotaxis,

inflammation, cell death and repair. Examination of the levels of proteins in the red

module across samples highlighted both upregulation of individual proteins in post-

COVID19 patients versus healthy controls, and the co-upregulation of groups of

related proteins such as the CXCR3 chemokines (CXCL9, CXCL10 and CXCL11),

and IL1A (interleukin-1A) and its antagonist IL1RN (**Figure 3B**). We used the

STRING database to visualize known or predicted relationships between proteins in

the module (**Figure 3C**, Methods). To highlight putative key proteins in the red and

blue modules in a data-driven way, we identified hub proteins, defined as those that

are highly interconnected in the proteomic network defined by WGCNA

(**Supplementary File 1J**). This analysis identified CASP3 (caspase-3), EPCAM

(epithelial cell adhesion molecule), F3 and MB as hub proteins in the red module.

Notably, F3 and MB, an oxygen binding protein release of which is linked to muscle

damage, were also identified as upregulated in the univariate differential abundance

analysis (**Figure 2B-C**). CASP3 is a protein involved in cell death, EPCAM and

KRT19 (Keratin-19) are indicative of epithelial cell debris within the BAL, and TGFA

(transforming growth factor A) is an EGFR ligand involved in EC repair. The

presence of CASP3, EPCAM, KRT19 and TGFA in the red eigenprotein module

therefore suggests that one of the key features of the post-COVID19 airway is the

presence of ongoing epithelial injury and repair.

As with the red module, blue module proteins were predominantly upregulated in

post-COVID19 versus healthy control BAL (**Figure S4A**). The blue module was

larger than the red module, containing 108 proteins involved in a wide range of

biological activities. Several members were involved in cell adhesion and immune

cell signaling. The hub proteins in the blue module were CD93 (Complement

component C1q receptor), COMP (Cartilage oligomeric matrix protein), IGFBP3

(Insulin-like growth factor-binding protein 3), IL1R2 (Interleukin-1 receptor type 2),

LYVE1, MMP2 (72 kDa type IV collagenase), NCAM1 (Neural cell adhesion molecule

1), SELL (L-selectin), TIE1 (Tyrosine-protein kinase receptor Tie-1), TNXB

(Tenascin-X) and VASN (Vasorin) (**Figure S4B**). Of these, LYVE1 and VASN were

also identified in the differential abundance analysis.

In contrast to the BAL network analysis, no protein modules in plasma were

associated with case-control status. These results suggest that persistent post-

COVID19 respiratory abnormalities have a demonstrable proteomic signature in BAL

that is distinct compared to that of healthy control BAL. In contrast, we were unable

to detect changes in the plasma proteome of post-COVID19 patients, even with the

enhanced statistical power provided by the WGCNA method.

CXCR3 ligands and signs of ongoing epithelial damage correlate with airway T cell

and monocyte responses

Given that the airways of post-COVID19 patients displayed a distinct proteome

alongside elevated numbers of T cells, B cells and NK cells, we next sought to

determine which specific proteins might be linked to distinct immune cell populations.

Testing for associations between BAL fluid proteins and immune cell composition in

post-COVID19 patients revealed several significant findings (**Figure 4A and**

Supplemental file 1K). The proportion of monocytes in the airways was significantly

associated with a range of airway proteins, including the CCR7 ligand CCL19, the

CXCR3 ligands CXCL9 and 11, TRAIL (TNFSF10), and BAFF (TNFSF13B) (**Figure**

4A). CXCL9 and 11 also positively correlated with lymphocyte and T cell frequencies

and negatively correlated with airway macrophage frequencies in the BAL (**Figure**

4A). T cell frequencies were also positively correlated with SH2D1A (otherwise

known as SLAM associated protein or SAP).

Analysis of combined data from healthy controls and post-COVID19 patients

revealed a composite score reflecting CXCL9, CXCL10 and CXCL11 levels, CXCL9,

CXCL10 and CXCL11, although no significant correlation was seen with $CD3^+CD56^+$

NKT cells (**Figure 4B**). Within the post-COVID19 data set (as CD16 was not present

in historic flow data used for healthy controls), total monocyte frequencies also

correlated with average CXCR3 ligand expression (**Figure 4C**). Analysis of

subpopulations revealed the proportion that were intermediate ($CD14^+CD16^+$)

monocytes positively correlated with CXCR3 ligands, while $CD14^+$ monocytes

displayed a negative correlation, and $CD16^+$ monocytes displayed no correlation

(**Figure 4C**). T cell proportions in the airways correlated tightly with the concentration

of CD8a protein, but not CD4, in the BAL (**Figure 4D**), suggesting the increased

airway T cells are most likely the result of increased $CD8^+$ T cell frequencies.

Given the robust correlation of the CXCR3 ligands, particularly with T cells, we next

sought to determine the relationship between T cell frequencies and other members

of the red module, specifically those indicative of ongoing epithelial damage in the

post-COVID19 airways. CD8a correlated strongly with the concentrations of CASP3

and EPCAM, concomitant with two of the differentially expressed proteins: MB and
DPP4 (**Figure 4E**). Collectively, these data suggest that proteins linked to the
recruitment of T cells, especially cytotoxic T cells, are strongly associated with
proteins that are both indicative of ongoing epithelial damage and upregulated in the
airways post-COVID19.

To further evaluate this and confirm the presence of increased damage in the post-
COVID19 airway, we measured DPP4, alongside 2 markers of damage not analyzed
through Olink, albumin and lactate dehydrogenase (LDH) in an expanded cohort of
healthy controls and post-COVID19 patients (**Figure 4F**). All 3 molecules were
significantly upregulated in the airways of patients post-COVID19 compared to
healthy controls, validating the observations made by Olink and confirming the
presence of ongoing damage within the respiratory tract in patients previously
hospitalized for COVID19.

Distinct myeloid populations are present in the BAL compared to the peripheral blood
but do not correlate with ongoing airway damage post-COVID19

Dysfunction of circulating classical monocytes is a hallmark of the initial, acute phase
of COVID19 infection (Mann et al., 2020). Given the correlations observed between
different airway monocyte populations and specific proteins in the BAL identified by
Olink, we further investigated the nature of airway and circulating myeloid cells in a
subgroup (n = 21) of post-COVID19 patients using high-parameter spectral
deconvolution cytometry. Unbiased FlowSOM analysis of the airway and circulating
myeloid cells revealed 10 distinct cell populations (**Figure 5A**), with marker analysis
suggesting these populations could be assigned to known subsets of monocytes or
dendritic cells (DCs). The circulation was dominated by $CD14^+$ classical monocytes
(metacluster 1), which constituted most myeloid cells identified, while the airways
were more heterogenous, with the presence of intermediate monocytes, non-
classical monocytes and DCs (**Figure 5B**). Conventional gating of these myeloid
subsets (as shown in **Methods Figure 2**) confirmed these observations, with
classical monocytes being most abundant in the circulation, while $CD16^+$ monocytes
were more frequent in the airways (**Figure 5C**). In comparison, DCs were identifiable
in both sites as pDCs, cDC1s and cDC2s, although were infrequent (**Figure 5D**).
Furthermore, airway monocyte activation status (as determined by CD86 and HLA-
DR expression) was not dependent on acute disease severity (**Figure 5E**). Likewise,
correlation of airway LDH and albumin concentrations revealed no strong

associations between the relative abundance of different myeloid cells and ongoing

damage in the respiratory tract after COVID19 (**Figure 5F**); nor was there any

association between these cell types and DPP4 concentrations. Taken together this

indicates that while myeloid cell frequencies in the airways are associated with a

specific airway proteome landscape, this likely has limited association with ongoing

tissue damage after SARS-CoV-2 infection.

The post-COVID19 airway is enriched for activated, tissue resident T cells

The post-COVID19 airway showed significantly increased T cell numbers (**Figure**

1C), associated with a proteome linked to ongoing epithelial damage and repair

(**Figure 2**). FlowSOM analysis of the airway and circulating lymphocytes indicated

that 12 metaclusters with distinct protein expression profiles were present (**Figure**

6A). Several metaclusters were unique to either the blood or the airways, with

specifically clusters 1 and 10 only present in the airways, and cluster 5 only present

in the blood (**Figure 6B-C**). Marker expression analysis identified these metaclusters

(as described in **Figure 6B**), with the differential clusters being identified as tissue-

resident memory CD4 and CD8 T cells (metaclusters 1 and 10), and naïve CD4 T

cells (metacluster 5). Manual gating of T cell populations showed that while the blood

was enriched for naïve CD4 and CD8 T cells, the airways contained populations of

antigen-experienced CD4 and CD8 T cells (**Figure 6D**). Additionally, the airways

contained increased proportions of activated and tissue-resident memory (TRM) CD4

and CD8 T cells compared to blood (**Figure 6D**). Proportions of $\gamma\delta$ T cells and NK

cells in the airways and blood were comparable however there was a significant

increase in NKT cell proportions compared to blood (**Figure 6E**). Comparison of the

T cell dynamics in the post-COVID19 airways showed that airway CD4 T cells retain

a highly tissue resident phenotype (CD69$^+$CD45RA$^-$), with few naïve (CD45RA$^+$) CD4

T cells observed, and the frequency of these 2 cell populations remains relatively

static, irrespective of the total number of CD4 T cells found in the airways (**Figure**

6F). In comparison, as CD8 T cell numbers increased in the airways, the proportion

displaying a CD45RA$^-$CD69$^+$ phenotype significantly increased, while those with a

CD45RA$^+$ phenotype declined (**Figure 6F**).

In line with activated CD8 T cells, rather than activated CD4 T cells, being linked to

ongoing epithelial damage in the post-COVID19 airway there was a correlation (r >

0.4) between CD8, but not CD4, T cell proportions in the airways and the

concentrations of airway albumin and LDH (**Figure 6G**); this correlation was stronger

when only CD69$^+$ CD8 T cells were analyzed (r = 0.5, p < 0.05 for both Albumin and

LDH). LDH most significantly correlated with the proportion of CD69$^+$ CD103$^-$ CD8 T

cells in the airways (r = 0.7, p < 0.001), while albumin most significantly correlated

with the proportion of CD69$^+$ CD103$^+$ CD8 T cells in the airways (r = 0.6, p < 0.001),

highlighting distinct markers of damage were linked to different phenotypes of CD8 T

cells in the airway. Of note however, the CD8 T cell frequency did not correlate with

the concentration of DPP4 in the airways (**Figure 6G**). Deeper analysis revealed that

albumin concentrations were associated with reduced expression of molecules

associated with T cell activation on both CD103$^+$ and CD103$^-$ CD69$^+$ CD8 T cells,

most notable CD28 and CD38 (**Figure 6H**). LDH concentrations meanwhile were

linked to downregulation of CD127 and, especially on CD103$^+$ CD69$^+$ CD8 T cells,

but upregulation of CD69 and CD27 (CD69: r = 0.5, p < 0.05; CD27: r = 0.6, p < 0.05,

Figure 6H). In contrast individuals with higher concentrations of DPP4 in the airways

appeared to possess CD8 TRM with higher expression of CRTH2 and CD38 (**Figure**

6H). No relationship was seen between the expression of activation markers on the

surface of CD8 TRM and the severity of disease in hospital (**Figure S5**). Taken

together, these results highlight the connection between T cells in the airways,

specifically CD8 TRM, and ongoing epithelial damage after recovery from COVID19,

and indicate differential CD8 T cell activation status may be associated with types of

damage within the airways.

The enhanced airway immune cell frequencies seen post-COVID19 decline over time

Acute COVID19 can result in persistent respiratory symptoms, and the data here

highlight the presence of substantial immunological and proteome alterations in the

airways of patients hospitalized with COVID19 up to 6 months after discharge. To

determine if these changes to the airways reduced over time, we examined 3

patients with continued lung CT abnormalities greater than 1 year following discharge

(**Table S3**). The total number of BAL cells recovered was greatly reduced in all 3

patients between the initial bronchoscopy and the 1 year follow up bronchoscopy,

down to comparable levels in healthy control airways (**Figure 7A**). Similarly, numbers

of T cells, B cells, NK cells and NKT cells were reduced to nearly or within the normal

range seen in the airways of healthy individuals (**Figure 7B**). In the 2 individuals with

elevated lymphocytes the ratio of CD4 to CD8 T cells increased (**Figure 7C**). In

accordance with this the proportion of CD8, but not CD4, T cells trended to decrease,

although the proportion of each that were of a TRM or activated (CD69$^+$) phenotype,

remained similar between the 2 time points (**Figure 7D**). Fitting with progressive

recovery trajectory airway DPP4 concentrations declined in the 2 patients with

elevated concentrations at the first bronchoscopy (**Figure 7E**), while CT abnormality

was also reduced in all 3 patients between the first CT and the follow up (**Figure 7F**).

Interestingly LDH was however increased between the first and second visit, while

albumin concentrations were unchanged, but also within the range of healthy controls

at both time points for all 3 patients analyzed (**Figure 7G**).

Collectively, our findings show ongoing changes to the immune and proteome

landscape of the airways, characterized by increased T cells and markers of

epithelial damage, several months after recovery from the acute phase of COVID19.

These changes, and lung pathology, do however appear to resolve over the longer (>

1 year) term.

Discussion

Recovery from acute SARS-CoV-2 infection is associated with a wide range of

persistent symptoms including ongoing respiratory pathology. Here we examine the

airway and circulating landscape of patients previously hospitalized with COVID19,

finding they possess a distinct proteome and immunological profile in their airways,

but not peripheral blood, 3 to 6 months post recovery from acute infection. While

there is substantial heterogeneity between patients, common upregulated signals

include proteins associated with ongoing cell death, epithelial damage and tissue

repair; features that correlate with the presence of increased numbers of activated

tissue resident CD8 T cells within the airways. Importantly, preliminary evidence

suggests this altered airway landscape does improve over the long term, with

reductions in airway immune cell numbers 1 year post discharge from hospital.

The acute response to SARS-CoV-2 infection is characterized by upregulation of a

wide diversity of plasma proteins including members of the IFN pathway and their

interferon stimulated genes (ISGs), chemokines, cytotoxic proteins, and markers of

epithelial damage (Arunachalam et al., 2020; Filbin et al., 2021; Gisby et al., 2021).

More severe disease is associated with increased concentrations of inflammatory

proteins such as IL-6, TNF, GM-CSF, IL-1RN and IL-18 (Arunachalam et al., 2020;

Filbin et al., 2021; Thwaites et al., 2021). A similar pattern of upregulated proteins,

especially chemokines like CXCL10 and cytokines such as IL-6, is seen in the

airways during acute COVID19 (Liao et al., 2020; Saris et al., 2021; Szabo et al.,

2021). Here, we show that 3 to 6 months after SARS-CoV-2 infection, despite the

presence of ongoing respiratory morbidity, the majority of the plasma proteins

differentially expressed during acute disease appear to have returned to similar

concentrations to those seen in healthy controls, and even data dimension reduction

approaches such as WGCNA fail to highlight any significant associations between

COVID19 infection and the plasma proteome months later.

In contrast, the post-COVID19 airways continue to display an abnormal proteome.

This displayed both shared and distinct features to that seen in acute disease.

Proteins linked to inflammation featured less prominently than in acute COVID19;

instead, we observed airway upregulation of proteins involved in epithelial damage

and repair (e.g. the EGFR ligand AREG and the epithelial marker KRT19). Matrix

metalloproteinase-3 (MMP-3), which regulates the extracellular matrix (ECM), was

also differentially upregulated in the post-COVID19 airway. MMP3 and AREG are

both upregulated after influenza A virus (IAV) infection *in vivo* in mice, and *in vitro* in
human fibroblasts and epithelial cells (Boyd et al., 2020); and these proteins are both
linked to epithelial repair and fibrosis in the lungs e.g. (Morimoto et al., 2018;
Yamashita et al., 2011).

The elevated concentrations of both lactate dehydrogenase and albumin in the
airways provide further evidence of ongoing cell death and damage to the barrier
integrity within the respiratory tract post-COVID19. This observation is reinforced by
the upregulation of a module of proteins in the BAL of post-COVID19 patients whose
individual members link epithelial damage (EPCAM, KRT19), cell death (CASP3) and
epithelial repair (TGFA), but also suggest a connection between these processes and
factors involved immune cell recruitment and survival (CXCL9, CXC10, CXCL11, IL-
7). These markers of ongoing damage and repair tightly correlate with the frequency
of T cells, especially CD8 TRM in the airways. In mouse models of severe acute
respiratory virus infection CD8 T cells have long been known to act as a double-
edged sword. Although the cytotoxic molecules and cytokines they release are
essential for clearing virus, they can also cause tissue damage and immune
pathology (reviewed in (Duan and Thomas, 2016; Schmidt and Varga, 2018)). While
the presence of pre-existing virus specific CD8 TRM in the airways is thought to be
highly protective against a re-encounter with the same virus in both mice and man
(Jozwik et al., 2015; Wu et al., 2014) almost nothing is known regarding their role in
long-term respiratory viral pathology, especially in humans. This is primarily due to
the lack of relevant samples collected during the recovery period. However, the data
shown here for SARS-CoV-2 may provide a potential insight, supporting the concept
that sustained activation of CD8 TRM in the airways, long after recovery from acute
disease, may contribute to ongoing immune pathology through sustained damage to
the respiratory epithelium.

The mechanism behind the increased number of CD8 TRM in the airways is unclear,
although another study has also reported detecting virus specific CD8 T cells in lung
tissue up to a year post-infection (Grau-Exposito et al., 2021). Both virus specific
CD4 and CD8 T cells rapidly expand in the circulation and airways of patients
following SARS-CoV-2 infection, leading to the formation of TRM (Szabo et al.,
2021). The majority of these activated effector T cells rapidly contract after resolution
of acute disease. In mice Slutter *et al* have shown that lung CD8 TRM are more
apoptotic than CD4 TRM after IAV infection, resulting in a more rapid decline in their
number. They also observed that the lungs of a mouse that had previously

experienced IAV infection more robustly maintained CD8 TRM compared to an
uninfected lung, showing that severe infection promotes a pro-TRM niche (Slutter et
al., 2017). This fits with our observation that while CD8 TRM numbers dynamically
change dependent on the concentration of damage and proteins in the airways, and
indeed longitudinally in the same individuals, CD4 TRM remain relatively static. A
number of factors likely contribute to the heterogeneity of the CD8 TRM niche in the
post-COVID19 airway. Firstly, while all our post-COVID19 samples were taken from
patients who tested negative for SARS-CoV-2 by qPCR immediately prior to
bronchoscopy, persistent antigen has been observed months after other respiratory
infections such as IAV (Kim et al., 2010), and antigen depots in SARS-CoV-2 could
drive ongoing cytotoxic activity and maintenance of CD8 TRM. Secondly, the
persistence of lung resident TRM is also reliant on the availability of local T cell
survival signals such as IL-7 (Szabo et al., 2019) and the CXCR3 ligands, which are
known to be involved in airway recruitment and retention of CD8 memory T cells in
murine IAV infection (Slutter et al., 2013). We found that both IL-7 and the CXCR3
ligands are part of the protein network that is maintained in the post-COVID19
airway. These proteins display a heterogeneous pattern of upregulation across post-
COVID19 patient samples (**Figure 3B**) and correlate with airway T cells and CD8a
concentrations. Lastly there is also some evidence of ongoing aberrant inflammation
after acute infection and the development of autoantibodies in some patients recently
recovered from COVID19 (Lucas et al., 2020; Wang et al., 2020). It is likely that
these different mechanisms act in concert to shape the number and function of CD8
TRM, and other immune cells, in the post-COVID19 airway, and the scale and
duration of ongoing epithelial damage and respiratory pathology observed.

One factor that does not appear to influence ongoing T cell recruitment and damage
in the post-COVID19 airway is the activation status of the myeloid compartment, in
particular monocytes. Functional impairment of monocytes and DCs in the peripheral
blood of acutely infected patients (Arunachalam et al., 2020; Laing et al., 2020; Mann
et al., 2020), and hyperactivation of airway monocyte populations, are canonical
features of severe acute SARS-CoV-2 (Liao et al., 2020; Szabo et al., 2021).
Moreover, early T cell phenotypes have been strongly linked to the status of these
monocytes (Filbin et al., 2021; Laing et al., 2020; Szabo et al., 2021). In our post-
COVID19 patients, however, the monocyte and myeloid pools in both the airways
and peripheral blood appear to have returned to relatively normal numbers and their
frequency does not correlate with indicators of ongoing epithelial damage. Likewise,
their activation status, as determined by HLA-DR and CD86 expression, is not

substantially different between individuals in line with other reports on circulating

monocytes from earlier stages of convalescence (Scott et al., 2020).

The airway monocyte frequency is, however, one of the few features to correlate with

a clinical biomarker of severity in acute disease, serum ferritin. High serum ferritin is

a prognostic marker used at presentation with acute COVID19 and linked to more

severe acute radiological findings (Carubbi et al., 2021; Ruan et al., 2020). Ferritin,

and transferrin, the protein responsible for transporting ferritin, are core components

of iron metabolism, and their dysregulation is associated with a range of lung

pathologies including decreased lung function and lung fibrosis (Ali et al., 2020; Lee

et al., 2020). In the respiratory tract the expression of CD71, the receptor that

scavenges transferrin from the environment, on alveolar macrophages is altered in

chronic respiratory disease (Striz et al., 1993), and the presence of CD71⁻ alveolar

macrophages, possessing both an immature and pro-fibrotic transcriptional

signature, has been linked to pulmonary fibrosis (Allden et al., 2019). In humans,

monocytes are recruited to the airways to differentiate into new AMs (Byrne et al.,

2020), and acute ferritin could be acting as a biomarker of severity of disruption to

AMs. This link is however challenging to elucidate, and it is possible that ferritin is

simply a proxy for the strength of the acute inflammatory response.

To our knowledge, this is the first study exploring the airway immune and proteomic

profiles in COVID19 patients between 3 months and 1 year post discharge from

hospital, and their links to ongoing respiratory pathology. Moreover, it is one of the

first studies to explore the human airway immune-proteome landscape after a

substantial period of time following any severe respiratory virus infection. Since all

samples were obtained more than 3 months post hospital discharge, when one might

expect normalization of the immune profile, the persistent immune abnormalities offer

possible explanations into the longevity of persistent respiratory morbidity post

SARS-CoV2 infection. In addition, these findings may be relevant to those suffering

long-term sequalae during convalescence from other viral pneumonias where data

are currently very limited.

We highlight a number of potential limitations of our study. Firstly, our data showing

immunological and proteomic changes in the BAL of post-COVID19 are generated on

patients undergoing clinically indicated bronchoscopy because of persistent

respiratory abnormalities. Whether our findings extend to individuals with no

radiological abnormalities or respiratory symptoms post-COVID19 remains unknown.

This selection bias also affects longitudinal sampling greater than 12 months post-
COVID19, since the majority of patients initially sampled between 3-6 months post-
COVID19 had shown sufficient improvement in respiratory pathology such that a
follow-up bronchoscopy was not indicated. The progressive resolution of radiological
abnormalities in the majority of post-COVID19 patients has been observed by others
(Han et al., 2021), and importantly within our study even the 3 patients with ongoing
pathology have a significantly improved CT and reduced immune cell infiltration
within their airways. This fits with the hypothesis that SARS-CoV2 infection can result
in organizing pneumonia, with subsequent changes reflecting ongoing epithelial
damage and healing parenchyma rather than established fibrosis (Kory and Kanne,
2020). This is both compatible with autopsy findings during the acute disease
(Wichmann et al., 2020) and the steroid-responsive nature of the acute pathology
(Horby et al., 2021).

Although we did not detect a plasma proteomic signature post-COVID19, this is likely
due to our limited sample size not being powered to detect small differences in
circulating proteins between post-COVID19 patients and healthy controls.
Examination of the distributions of p-values suggests that such differences may exist
(**Figure S3**) but will likely require future much larger cohort studies to reveal them.
Regardless, the absence of any correlation between the differentially expressed
proteins in the airways and their corresponding changes in the plasma points to the
limited utility of peripheral blood as an indicator of the pathological processes
ongoing in the lung.

Finally, as with most studies, we were limited to sampling the airways post-infection
and so did not have paired pre-infection samples for intra-individual comparisons.
Therefore, it is possible that some differences observed between healthy controls
and post-COVID19 patients could reflect a pre-infection phenotype that predisposed
them to developing prolonged sequelae. Indeed, one of the most differentially
expressed proteins in the airways, DPP4, is the binding receptor for another
coronavirus MERS (Raj et al., 2013), and postulated to be capable of mediating
some SARS-CoV-2 binding (Li et al., 2020). Thus, it is conceivable that pre-existing
upregulation of DPP4 increased susceptibility to post-COVID19 syndrome via
increased viral entry (i.e. reverse causation), rather than DPP4 upregulation
occurring in response to COVID19. However, the longitudinal reduction of DPP4
argues against this hypothesis. More generally, the majority of proteins and markers
upregulated are associated with ongoing lung pathology in other contexts (e.g. LDH),

and are absent or only present at very low concentrations in the healthy airway,

suggesting that their upregulation is more likely to be a consequence of COVID19

than a pre-disposing risk factor.

In summary, our study offers unique and novel insights into ongoing

immunopathology post-COVID19. In contrast to the inflammatory pathways observed

during acute disease, we found proteins associated with ongoing epithelial damage,

cell death, and repair were upregulated in conjunction with ongoing CD8 T cell

activation. These data indicate that significant immune pathways operate within the

tissue, presumably to facilitate repair and resolution, even in the absence of

peripheral inflammation. In the future it will be important to determine how such a

substantial shift in the immune landscape of the airways might affect the response to

a subsequent respiratory infection such as seasonal influenza. The progressive

improvement in respiratory pathology, even in this cohort with substantive

radiological abnormalities should be seen as a positive indicator for the long-term

prognosis for those with persistent morbidity. Moreover, the involvement of the

immune response suggests this recovery could be accelerated using immuno-

modulatory treatments, especially those designed against TH1 immune responses.

Funding

This work was supported by a Wellcome Trust Senior Fellowship 107059/Z/15/Z to

C.M.L., a Rosetrees Seed Fund to P.L.M. and J.A.H. (A2172) and an Imperial

College Healthcare NHS Trust BRC award to J.A.H. (RDF04). B.V. is funded by the

Joint Research Committee on behalf of a joint collaboration between CW+ and

Westminster Medical School Research Trust. K.B. is funded by an Asthma UK PhD

Studentship as part of the Asthma UK centre in allergic mechanisms of asthma

(AUK-BC-2015-01). R.J.S. is supported by a Wellcome Trust Senior Fellowship

(209458/Z/17/Z). J.E.P. is supported by a UKRI COVID19 Rapid Response Rolling

Call (MR/V027638/1), the Imperial College London Community Jameel and the

Imperial President's Excellence Fund, and a UKRI Innovation Fellowship at Health

Data Research UK (MR/S004068/2).

Acknowledgements

We thank Jack Gisby for statistical and analytical advice and Simone Walker for

technical assistance. We also thank the staff of Sir Alexander Fleming Building Flow

Cytometry Facility at Imperial College London for assistance with flow acquisition and

analysis. The schematic in Figure 1A was made using Biorender. We also thank Dr

Ryan Thwaites and Professor Peter Openshaw, Imperial College London, for

critically reading this manuscript before submission.

Author contributions:

BV and **PLS** designed the PHENOTYPE study and were involved in recruitment of

the post-COVID19 cohort. **PLS, CML, JEP** and **JAH** designed and conceived the

current study. **JAH** and **CML** co-ordinated the study. **BV**, **JT**, **CO**, **JG** and **PLS**

collected clinical samples and patient information for the post-COVID19 cohort. **RJH**

and **PLM** designed and were responsible for recruitment and sampling of the heathy

control cohort. **BV, KB** and **PPO** processed clinical samples for the post-COVID19

cohort. **PG** processed clinical samples for the heathy control cohort. **BV**, **KB, PPO**

and **PG** conducted flow cytometry and mediator measurements. **KS** measured LDH

and albumin. **KB** and **PPO** analysed the flow cytometry analysis. **AP** analyzed the

Olink proteomics data set. **PS** supervised the clinical aspects of the project, **JEP**

supervised the bioinformatic analysis. **RJS, PLM**, **CML** and **JAH** supervised the

laboratory preparation of samples and flow cytometry and mediator measurement

analysis. **BV**, **KB**, **PPO**, **AP**, **JEP**, **PLS, CML** and **JAH** were involved in data

interpretation. **JAH** wrote the initial draft of the manuscript and **BV**, **KB**, **PPO**, **AP**,

JEP, **PLS** and **CML** carried out major writing of the paper. All the authors reviewed

and approved the submitted manuscript. For information on proteomics contact

James E Peters, j.peters@imperial.ac.uk; For clinical information contact Pallav L

Shah, pallav.shah@imperial.ac.uk; For epithelial cell biology and repair contact Clare

M Lloyd, c.lloyd@imperial.ac.uk; For immune cell phenotyping contact James A

Harker, j.harker@imperial.ac.uk.

Figure legends

Figure 1: Increased airway lymphocytes in the 3 to 6 months post COVID-19

(A) Schematic of study design. BAL and blood were sampled from healthy donors

and at > 80 days after hospital discharge from post-COVID19 patients. Traditional

and spectral flow cytometry and Olink proteomics was performed on BAL and plasma

and correlated with clinical parameters. **(B)** Left: Total number of cells in BAL from

healthy controls and post-COVID19 patients. Right: total number of cells in BAL from

post-COVID19 patients, stratified according to severity of the acute illness. **(C)** Total

cell numbers of immune populations ($x10^6$/ml) in BAL from healthy controls and post-

COVID19 patients, based on gating shown in Methods Figure 1.

Data are presented as mean ± SEM. Healthy controls n = 16, post-COVID19 patients

n = 21, moderate n = 6, severe n = 8, very severe n = 7. Statistical significance was

tested by Mann Whitney U test or Kruskal Wallis test + Dunn's multiple comparison

test. *$P < 0.05$, **$P < 0.01$, ***$P < 0.005$, ****$P < 0.001$.

Figure 2: A distinct proteome is present in the post COVID-19 airway

436 proteins in BAL and plasma 435 proteins were measured using Olink

immunoassays in post-COVID19 patients (n = 19) and healthy controls (n = 9). **(A)**

Principal component analysis (PCA) of BAL and plasma proteomes: each point

represents a sample. **(B)** Left: heatmap displaying Z-score normalised protein

abundance for the 22 proteins that were significantly differentially abundant (5%

FDR) between post-COVID19 and healthy controls in BAL. Samples have been

ordered by case control status and then by peak severity during acute COVID-19

infection. Proteins are ordered by hierarchical clustering. Right: heatmap for these

same 22 proteins in plasma, presented in the same order as for BAL. **(C)** Volcano

plot showing differentially protein abundance analysis between post-COVID19

patients and healthy controls in BAL. Nominal $-\log_{10}$ P values are shown.

Significantly differentially abundant proteins (5% FDR) are coloured in red and

labelled. **(D)** BAL and plasma normalised protein abundance (NPX) expression for

the 5 most significantly differentially abundance proteins between post-COVID19

patients and healthy controls. P_{BH} = Benjamini-Hochberg adjusted p-values. **(E)**

Correlation between the 22 differentially abundant proteins and immune cell

frequency in BAL.

Figure 3: A network of proteins linked to immune cell chemotaxis and cell
death is upregulated in the BAL post-COVID19
WGCNA of BAL proteome of post-COVID19 patients and healthy controls. **(A)**
Associations of protein modules identified by WGCNA with case-control status (post-
COVID19 or healthy). **(B)** Heatmap displaying Z-score normalised protein abundance
for the 37 proteins that form the 'red' protein module. Samples are ordered according
to clinical status. Severity refers to peak severity of the acute COVID19 episode.
Proteins are ordered by hierarchical clustering. **(C)** Right: Network representation of
proteins in the red module and their interconnections defined using String-db. An
edge in the network represents a relationship between proteins, coloured according
to the type of evidence for the connection (see Methods). Left: list of hub proteins
within the network (with hub proteins that were also significantly differentially
upregulated in post-COVID19 patient BAL highlighted in red).

Figure 4. CXCR3 ligands and markers of epithelial damage correlate with CD8 T
cells in the airways
BAL immune cells and protein concentrations were analysed post-COVID19
infection. **(A)** Linear regression analysis was conducted between n = 435 proteins
measured in the BAL using the Olink platform and BAL immune cell frequencies
identified by flow cytometry as shown in Figure 1. A heatmap showing proteins with
the highest correlation versus 5 major immune cell frequencies is shown. **(B-C)** For
each sample, protein levels for CXCL9, -10 and -11, were normalised to the median
level in healthy controls. For each sample, the mean of the normalised values for the
3 proteins was calculated to provide a summary metric for CXCR3 chemokines. This
was then plotted against versus **(B)** T, NK and NKT proportions in post-COVID19
patients and healthy controls and **(C)** monocyte frequencies and subsets in post-
COVID19 patients only. **(D)** BAL T cell frequency versus CD4 and CD8a
concentrations as measured by Olink. **(E)** CD8a concentration versus CASP3,
EPCAM, MB and DPP4 in the airways. **(F)** DPP4, albumin and LDH concentrations in
the BAL determined by ELISA. Data are presented as median ± IQR. **(A)** Pearsons
correlation of n = 19 post-COVID19 patients, the r value is shown. **(B-E)** Each point
represents an individual patient, linear regression line +/- 95% confidence intervals
are depicted, and r and p values from Pearsons correlation are stated. **(F)** represents
n = 38 post-COVID19 and n = 20 healthy control individuals. Statistics were
conducted using Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P <
0.001. pCOVID = post-COVID19.

Figure 5. Myeloid cell frequencies are not linked to indications of ongoing
damage in the post-COVID19 airway

BAL and blood immune cells from post-COVID19 patients were analyzed by spectral
deconvolution cytometry. **(A)** Heatmap of normalised median expression of myeloid
cell modulatory and subset markers by clusters of myeloid cells in the airways
identified by FlowSOM analysis. **(B)** Violin plot showing frequencies of each cluster in
BAL and blood. **(C)** Violin plots showing classical, non-classical and intermediate
monocyte subsets as proportions of live leukocytes in BAL and blood identified by
manual gating. **(D)** Violin plots showing pDC, cDC1 and cDC2 cell proportions in BAL
and blood. **(E)** Geometric mean fluorescence intensity of activation markers
expressed by CD11c$^+$ monocytes. **(F)** Pearson's correlation between BAL myeloid
subsets (as a % of leukocytes) and airway LDH, albumin and DPP4. Data are
presented as median ± IQR. Each point represents an individual patient. Statistical
significance for **(B), (C)** and **(D)** was tested by Mann-Whitney U test. *P < 0.05, **P <
0.01, ***P < 0.005, ****P < 0.001.

Figure 6. The airways of post-COVID19 patients are enriched for activated CD8
TRM cells

BAL and blood immune cells from post-COVID19 patients were analyzed by spectral
deconvolution cytometry.**(A)** Heatmap of normalised median expression of T cell
modulatory and subset markers by clusters of T cells in the airways identified by
FlowSOM analysis. **(B)** Violin plot showing frequencies of each cluster in BAL and
blood. **(C)** tSNE projection of clusters identified by FlowSOM analysis in BAL and
blood. **(D)** Violin plots showing CD4+ and CD8+ T cell subsets as proportions of all T
cells in BAL and blood identified by manual gating. **(E)** Violin plots showing gd, NK,
NKT and MAIT cell proportions in BAL and blood. **(F)** Pearson correlations between
total airway CD4$^+$ and CD8$^+$ T cell numbers and subsets. **(G)** Heatmap depicting
Pearson correlation between different T cell populations (as a % of BAL leukocytes)
and the concentration of DPP4, LDH and Albumin in the airways. **(F)** Pearson
correlations between the gMFI of LDH and albumin. Data are presented as median ±
IQR. Each point represents an individual patient. **(A, B, E** and **F)** represent n = 20
individuals. (**C**) represents an equal number of cells from n = 10 patients combined.
(**G** & **H**) represents n = 18 individuals. Statistical significance for **(B), (D), (E)** and **(G)**
was tested by Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P <
0.001.

Figure 7. Reduced cellularity in the airways one year after initial bronchoscopy

post-COVID19

(A) Total cell counts (left) and proportions of lymphocytes (right) in the BAL following

first bronchoscopy and one year follow-up bronchoscopy. **(B)** Cell counts of

lymphocyte populations in the BAL following first bronchoscopy and one year follow-

up bronchoscopy. **(C)** Cell counts of myeloid populations in the BAL following first

bronchoscopy and one year follow-up bronchoscopy. **(D)** Proportions of T cell

subsets in the BAL following first bronchoscopy and one year follow-up

bronchoscopy. **(E)** LDH (left) and albumin (right) measurements in BAL following first

year bronchoscopy and one year follow-up bronchoscopy. **(F)** Percentage of

abnormal CT following first year CT and one year follow-up CT. **(G)** BAL LDH and

albumin quantification following first year bronchoscopy and one year follow-up

bronchoscopy. Each point represents a single patient. Green shading indicates

median+/-IQR for proportions of populations and mediator levels observed in healthy

airways.

824
825

Methods

Post-COVID-19 patient recruitment

Post-COVID19 bronchoalveolar lavage fluid (BAL) was obtained from patients recruited to the PHENOTYPE study (NCT 04459351), an observational, longitudinal study recruiting patients at Chelsea and Westminster Hospital, London. 38 samples were collected from patients requiring sampling for clinical purposes. Ethical approval for the study was given by Yorkshire & The Humber - Sheffield Research Ethics Committee (IRAS 284497).

Patients who met the inclusion and exclusion criteria were recruited to the PHENOTYPE study:

Inclusion criteria for the study were:

- Aged 18 years or older
- Previous confirmed COVID-19 infection (positive PCR or antibody)
- Attending a respiratory follow-up outpatient appointment for follow-up of persistent respiratory symptoms following visit post hospital attendance with COVID-19. infection or referred by the community for covid-related symptoms.

Patients were seen at approximately 4-6 weeks (Visit 1) and 3 months (Visit 2) following discharge from hospital or referral (if referred from the community). Patients underwent clinical assessment at both visits, including collection of demographic data, clinical history and clinical examination and assessment of vital parameters (heart rate, peripheral oxygen saturations, blood pressure reading and temperature). They also underwent clinical blood tests (including full blood count, renal function, liver function, C-reactive protein (CRP), ferritin, fibrinogen, D-dimer and pro-calcitonin). Patients had a computed tomography (CT) scan of the lungs approximately 3 months post discharge from hospital. In patients with abnormal CT findings, or persistent respiratory symptoms, a bronchoscopy and lavage was performed as part of clinical work-up. Patients underwent formal lung function tests (including spirometry, lung volumes and gas transfer) near the time of the bronchoscopy (usually during the days immediately preceding the procedure). Further follow-up was determined on the basis of clinical need, with a maximum follow up period of up to 2 years post hospital discharge or referral.

Post-COVID19 bronchoalveolar lavage (BAL) sampling

862 Bronchoscopy was performed under conscious or deep sedation. 150 ml of normal
863 saline were instilled into the most affected segment (as determined by CT imaging),
864 in 50 ml aliquots. 10 ml of fluid return was used for the scientific analysis described in
865 this paper.
866

Healthy volunteer recruitment and sampling
Control, uninfected bronchoalveolar lavage was obtained from healthy donors
(collected between April 2016 and December 2019). Ethical approval for the study
was granted by the Research Ethics Committee (15/SC/0101) and all patients
provided informed written consent as described previously (Allden et al., 2019; Byrne
et al., 2020; Invernizzi et al., 2021). Briefly, 240 ml aliquots of warmed sterile saline
were instilled in the right middle lung and aspirated by syringe. Lavage aliquots were
pooled for each subject. All subjects provided written, informed consent to participate
in the study. Healthy volunteers had no self-reported history of lung disease, an
absence of infection within the last 6 months and normal spirometry.
877

BAL processing
BAL samples were processed and stained on the day of sample collection. BAL was
strained through a 70μm filter and subsequently centrifuged (1800 rpm, 2 min, 4°C).
Supernatant was snap-frozen and stored at -80°C. Pellets were incubated in red
blood cell lysis buffer (155mM NH_4Cl, 10mM $KHCO_3$, 0.1mM
ethylenediaminetetraacetic acid, pH 7.4) for 10 minutes before washing and
resuspension in complete media (RPMI 1640 with 10% fetal calf serum, 2mM L-
glutamine, 100U/ml penicillin-streptomycin).
886

Blood processing
Peripheral blood was collected in EDTA coated vacutainers on the same day as
bronchoscopy. 1ml blood was centrifuged at 100g for 10 minutes (4°C), followed by
centrifugation at 20,000g for 20 minutes (4°C) to separate plasma, which was
subsequently stored at -80°C. 2ml blood from post COVID-19 patients was incubated
with red blood cell lysis buffer (155mM NH_4Cl, 10mM $KHCO_3$, 0.1mM
ethylenediaminetetraacetic acid, pH 7.4) for 10 minutes before washing and
resuspension in complete media (RPMI 1640 with 10% fetal calf serum, 2mM L-
glutamine, 100U/ml penicillin-streptomycin). 2.5 ml blood from healthy controls was
used to isolate peripheral blood mononuclear cells (PBMC) by Percoll density
centrifugation, as per manufacturer's instructions.

Flow cytometry staining

For traditional flow cytometry, 2 - 5 x10^5 cells were plated, while for high parameter

analysis using the Cytek Aurora 1 x 10^6 cells from each site were used. Cells were

washed with PBS and incubated with either near-infrared (traditional flow cytometry)

or blue (Cytek Aurora) fixable live/dead stain (Life Technologies), as per the

manufacturer's instructions. Before incubation with human fc block (BD Pharmingen)

cells were washed with FACS buffer (1% FCS, 2.5% HEPES, 1mM EDTA) and

surface staining was performed at 4°C for 30 minutes using antibody panels as

described in the **Key Resources Table**. Surface staining was followed by washing

with FACS buffer and fixation with 1% paraformaldehyde for 10 minutes. Labelled

cells were acquired on a 4-laser BD Fortessa (traditional flow cytometry; BD

Bioscience) or 5-laser Cytek Aurora flow cytometer (Cytek Bio).

Flow cytometry analysis

Conventional flow cytometry data was analysed using FlowJo v 10.6 (Tree Star).

Data was pre-gated to exclude doublets and dead cells. In BAL samples CD45$^+$ cells

were selected, and immune cell populations were identified using the gating strategy

shown in **Methods Figure 1**. Percentages of the CD45$^+$ gate were calculated. In

blood samples, leukocytes were selected based on FSC and SSC and immune cell

populations were identified using the gating strategy shown in **Methods Figure 1**.

Percentages of total leukocytes were calculated. High-parameter spectral

deconvolution flow cytometry data from the Cytek Aurora was analysed using

Cytobank (Beckman). tSNE analysis was performed on 300,000 events from 11 files.

Iteration number was set to 1500 with a perplexity of 30 and theta of 0.5. FlowSOM

analysis was performed subsequently using hierarchical consensus clustering with

12 metaclusters, 100 clusters and 10 iterations. Manual gating of high parameter

cytometry data was carried out as shown in **Methods Figure 2**. Heatmaps were

generated from median fluorescence values in Prism 9.0 (GraphPad).

Quantification and statistical analysis for flow cytometry

Differences in means between two sample groups were compared using two-tailed

Mann-Whitney U tests. Multiple group comparisons were done using Kruskal Wallis

ANOVA followed by Dunn's post-test. Spearman-Rank correlations were used to

correlate clinical blood parameters with immune cell populations. Analysis was

performed in GraphPad Prism. For all figures, * denotes p value < 0.05, ** denotes p

value < 0.01 and *** denotes p value < 0.001.

Proteomic assays

Plasma and BAL proteomic measurement was performed using the Olink proximity

extension immunoassay platform. Five 92-protein multiplex Olink panels were used

('Inflammation', 'Immune Response', 'Cardiometabolic', Cardiovascular 2',

'Cardiovascular 3'), providing measurements of 460 protein targets per sample.

Cryopreserved BAL and plasma samples were thawed on ice and mixed well by

pipetting before plating 88 samples per plate ensuring case/control balance and

random well ordering to prevent confounding of technical and biological effects. For

BAL samples, a pilot study was performed using three control samples and three

post-COVID19 samples (severe group) to determine optimal dilution parameters.

Ultimately BAL was used neat. Since a small number of proteins were assayed on

more than one panel, we measured a total of 435 unique proteins. We removed

duplicate assays at random prior to subsequent analyses.

Proteomics analyses

Proteomic data was normalised using standard Olink workflows to produce relative

protein abundance on a log2 scale ('NPX'). BAL and plasma proteomic data were

normalised separately. Quality assessment was performed by (1) examination of

Olink internal controls and (2) inspection of boxplots, relative log expression plots,

and PCA.

PCA was performed using singular value decomposition. Following these steps, 2

clear outlying samples were removed from the BAL dataset.

To identify proteins that were differentially abundant between case and controls, for

each protein we performed linear regression (lm function in R) with case/control

status as the independent variable and protein level (NPX) as the dependent

variable. P-values were adjusted for multiple testing using the Benjamini-Hochberg

procedure (p.adjust function in R). A 5% false discovery rate was used to define

statistical significance.

We used the WGCNA R package (Langfelder and Horvath, 2008; Zhang and

Horvath, 2005) to create a weighted protein correlation network. Prior to WGCNA

analysis, protein data were scaled and centred, and missing data were imputed using

the R caret package. We used the WCGNA adjacency function to produce a weighed

network adjacency matrix, using parameters "type=signed" and "power=13". This

soft-thresholding power was selected as the lowest power to achieve approximate

scale-free topology. We next defined a topological overlap matrix of dissimilarity

using the TOMdist function. Clusters ('modules') of interconnected proteins were

identified using hierarchical clustering and the cutreeDynamic function with

parameters: method="hybrid", deepSplit=2, minClusterSize=15. We then tested

association of these modules with case/control status. Multiple testing correction was

performed to account for the number of modules. We report both Benjamini-

Hochberg and Bonferroni adjusted p-values to provide two levels of stringency.

To assess the distribution of p-values from the differential protein abundance

analyses, we plotted histograms and constructed QQ plots. QQ plots were made by

comparing the expected distribution of -log10 P values under the null hypothesis of

no proteomic differences between post-COVID19 patients and controls to the

observed p-values for the 435 proteins.

We performed pathway enrichment analysis for the 435 proteins measured. This was

performed using terms from KEGG database (**Supplementary File 1B**) and the

Reactome database (**Supplementary File 1C**).

Protein modules were visualised using STRING (https://string-db.org/), with known or

suspected interconnections between module members displayed as edges in a

network diagram. An edge represents a protein-to-protein relationship defined as

shared contributions to a particular function, and not necessarily implying physical

binding. In **Figure 3C**, edge colour indicates the type of evidence for the relationship:

turquoise represents known interactions from curated databases; magenta

represents experimentally determined interactions; green represents predicted

Interactions from gene neighbourhood analysis; red represent predicted interactions

from gene fusions, blue represent predicted Interactions from gene co-occurrence;

light green represents interaction from text-mining; black represents interaction from

co-expression data, and violet represents information from protein homology.

1001

CXCR3 chemokine composite score

To create a composite score that reflected the CXCR3 chemokines (CXCL9,

CXCL10 and CXCL11), we used the following approach. For each sample, protein

levels for CXCL9, -10 and -11, were normalised to the median level in healthy

controls (to avoid unduly weighting the score towards chemokines with higher NPX

values). For each sample, the mean of the normalised values for the 3 proteins was

then calculated to provide a summary metric for CXCR3 chemokines.

1009

1010

Quantification of mediators in BAL

DPP4 (R&D systems, DY1180) and albumin (Bethyl Laboratories, E80-129)

concentrations in the BAL were quantified by ELISA according to manufacturer's

instructions. LDH concentrations were quantified using an *in vitro* toxicology assay

(Sigma, TOX7). Briefly, 25µl of BAL sample were incubated with 50µl of LDH assay

reaction mixture. After 30 minutes, the reaction was stopped with 7.5µl 1N HCL and

absorbance was measured at 490nm with background correction at 690nm. All

absorbances were measured using a SpectraMax i3x (Molecular Devices).

1019

1020 **Key Resources Table**

Reagent or Resource	Source	Identifier	Dilution
Antibodies			
Anti-Human CD69, BUV395	BD Biosciences	564364	1:20
Anti-human CD8, BUV496	BD Biosciences	612942	1:100
Anti-Human CD45RA, BUV563	BD Biosciences	612927	1:100
Anti-Human CD11c, BUV661	BD Biosciences	612968	1:100
Anti-Human CD56, BUV737	BD Biosciences	612767	1:100
Anti-Human CD3, BUV805	BD Biosciences	612896	1:100
Anti-Human IgD, BV421	Biolegend	348226	1:100
Anti-Human CD16, SuperBright436	ThermoFisher	62-0166-42	1:100
Anti-Human CD25, eFluor450	ThermoFisher	48-0257-42	1:100
Anti-Human CD20, BV480	BD Biosciences	566132	1:100
Anti-Human CD127, BV510	Biolegend	351332	1:50

Anti-Human HLA-DR, BV570	Biolegend	307638	1:100
Anti-Human CD28, BV605	Biolegend	302968	1:100
Anti-Human CD38, BV650	Biolegend	356620	1:100
Anti-Human CD15, BV711	Biolgend	323050	1:100
Anti-Human CD279, BV750	Biolegend	329966	1:100
Anti-Human CD206, BV785	Biolegend	321142	1:20
Anti-Human CD45, QDOT800	ThermoFisher	Q10156	1:800
Anti-Human CXCR5, BB515	BD Biosciences	564624	1:50
Anti-Human CD169, AF488	R&D systems	FAB5197G	1:100
Anti-Human CD4, Spark Blue 550	Biolegend	344656	1:100
Anti-Human CD161, PerCP	Biolegend	3399334	1:20
Anti-Human CD27, BB700	BD Biosciences	566449	1:100
Anti-Human Siglec8, PerCP Cy5.5	Biolegend	347108	1:100
Anti-Human CD86, PerC eFLuor710	ThermoFisher	46-0869-42	1:100
Anti-Human CD141, PE	Biolegend	344104	1:20
Anti-Human TCRg/d, PEdz594	Biolegend	331226	1:100
Anti-Human TCRa/b PE Cy5	Biolegend	306710	1:100
Anti-Human CD11b, PE Cy7	Biolegend	301322	1:100

Anti-Human CD123, APC	Biolegend	306012	1:100
Anti-Human CRTH2, AF647	Biolegend	350104	1:100
Anti-Human CD14, Spark NIR	Biolegend	367150	1:100
Anti-Human CD1c, APC R700	BD Biosciences	566614	1:100
Anti-Human CD103, APC Cy7	Biolegend	350228	1:100
Anti-Human CD45, PerCP Cy5.5	ThermoFisher	45-0459-42	1:25
Anti-Human Siglec8, AF488	R&D systems	FAB7975G	1:100
Anti-Human CD19, BV421	Biolegend	302234	1:100
Anti-Human CD4, BV510	Biolegend	317444	1:100
Anti-Human CD117, BV605	Biolegend	313218	1:100
Anti-Human CD14, BV711	Biolegend	301838	1:100
Anti-Human CD16, BV785	Biolegend	302046	1:100
Anti-Human CD177, FITC	Biolegend	315804	1:100
Anti-Human Siglec8, PE	R&D systems	FAB7975P	1:100
Anti-Human CD56, PEdz594	Biolegend	318348	1:100
Anti-Human CD3, PE-Cy7	Biolegend	300420	1:100
Anti-Human CD206, APC	Biolegend	321110	1:100
Anti-Human FcE, AF700	Biolegend	334630	1:100

LIVE/DEAD Fixable NIR Cell Stain	ThermoFisher	L34976	1:1000
LIVE/DEAD Fixable Blue? Cell Stain	ThermoFisher	L34961	1:1000
TruStain FcX	Biolegend	422302	1:100
RPMI 1640	Gibco	21875091	

1021

1022

1023

1024

1025

References

Ali, M.K., Kim, R.Y., Brown, A.C., Donovan, C., Vanka, K.S., Mayall, J.R., Liu, G., Pillar, A.L., Jones-Freeman, B., Xenaki, D., *et al.* (2020). Critical role for iron accumulation in the pathogenesis of fibrotic lung disease. J Pathol *251*, 49-62.

Allden, S.J., Ogger, P.P., Ghai, P., McErlean, P., Hewitt, R., Toshner, R., Walker, S.A., Saunders, P., Kingston, S., Molyneaux, P.L., *et al.* (2019). The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med *200*, 209-219.

Arunachalam, P.S., Wimmers, F., Mok, C.K.P., Perera, R., Scott, M., Hagan, T., Sigal, N., Feng, Y., Bristow, L., Tak-Yin Tsang, O., *et al.* (2020). Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science *369*, 1210-1220.

Boyd, D.F., Allen, E.K., Randolph, A.G., Guo, X.J., Weng, Y., Sanders, C.J., Bajracharya, R., Lee, N.K., Guy, C.S., Vogel, P., *et al.* (2020). Exuberant fibroblast activity compromises lung function via ADAMTS4. Nature *587*, 466-471.

Byrne, A.J., Powell, J.E., O'Sullivan, B.J., Ogger, P.P., Hoffland, A., Cook, J., Bonner, K.L., Hewitt, R.J., Wolf, S., Ghai, P., *et al.* (2020). Dynamics of human monocytes and airway macrophages during healthy aging and after transplant. J Exp Med *217*.

Carubbi, F., Salvati, L., Alunno, A., Maggi, F., Borghi, E., Mariani, R., Mai, F., Paoloni, M., Ferri, C., Desideri, G., *et al.* (2021). Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. Sci Rep *11*, 4863.

Chen, Z., and Wherry, E.J. (2020). T cell responses in patients with COVID-19. Nat Rev Immunol *20*, 529-536.

Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez, S.I., Haupt, S., Frazier, A., *et al.* (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science *371*.

Docherty, A.B., Harrison, E.M., Green, C.A., Hardwick, H.E., Pius, R., Norman, L., Holden, K.A., Read, J.M., Dondelinger, F., Carson, G., *et al.* (2020). Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ *369*, m1985.

Drake, T.M., Riad, A.M., Fairfield, C.J., Egan, C., Knight, S.R., Pius, R., Hardwick, H.E., Norman, L., Shaw, C.A., McLean, K.A., *et al.* (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet *398*, 223-237.

Duan, S., and Thomas, P.G. (2016). Balancing Immune Protection and Immune Pathology by CD8(+) T-Cell Responses to Influenza Infection. Front Immunol *7*, 25.

Fabbri, L., Moss, S., Khan, F., Chi, W., Xia, J., Robinson, K., Smyth, A., Jenkins, G., and Stewart, I. (2021). Post-viral parenchymal lung disease of COVID-19 and viral pneumonitis: A systematic review and meta-analysis. medRxiv, 2021.2003.2015.21253593.

Filbin, M.R., Mehta, A., Schneider, A.M., Kays, K.R., Guess, J.R., Gentili, M., Fenyves, B.G., Charland, N.C., Gonye, A.L.K., Gushterova, I., *et al.* (2021). Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med *2*, 100287.

Gisby, J., Clarke, C.L., Medjeral-Thomas, N., Malik, T.H., Papadaki, A., Mortimer, P.M., Buang, N.B., Lewis, S., Pereira, M., Toulza, F., *et al.* (2021). Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. Elife *10*.

Grau-Exposito, J., Sanchez-Gaona, N., Massana, N., Suppi, M., Astorga-Gamaza,
A., Perea, D., Rosado, J., Falco, A., Kirkegaard, C., Torrella, A*., et al.* (2021).
Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nat
Commun *12*, 3010.
Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei,
C.L., Hui, D.S.C*., et al.* (2020). Clinical Characteristics of Coronavirus Disease 2019
in China. N Engl J Med *382*, 1708-1720.
Guler, S.A., Ebner, L., Aubry-Beigelman, C., Bridevaux, P.O., Brutsche, M.,
Clarenbach, C., Garzoni, C., Geiser, T.K., Lenoir, A., Mancinetti, M*., et al.* (2021).
Pulmonary function and radiological features 4 months after COVID-19: first results
from the national prospective observational Swiss COVID-19 lung study. Eur Respir J
57.
Han, X., Fan, Y., Alwalid, O., Li, N., Jia, X., Yuan, M., Li, Y., Cao, Y., Gu, J., Wu, H.,
and Shi, H. (2021). Six-month Follow-up Chest CT Findings after Severe COVID-19
Pneumonia. Radiology *299*, E177-E186.
Harker, J.A., and Lloyd, C.M. (2021). Overlapping and distinct features of viral and
allergen immunity in the human lung. Immunity *54*, 617-631.
Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N.,
Brightling, C., Ustianowski, A., Elmahi, E*., et al.* (2021). Dexamethasone in
Hospitalized Patients with Covid-19. N Engl J Med *384*, 693-704.
Invernizzi, R., Wu, B.G., Barnett, J., Ghai, P., Kingston, S., Hewitt, R.J., Feary, J., Li,
Y., Chua, F., Wu, Z*., et al.* (2021). The Respiratory Microbiome in Chronic
Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med *203*, 339-347.
Jozwik, A., Habibi, M.S., Paras, A., Zhu, J., Guvenel, A., Dhariwal, J., Almond, M.,
Wong, E.H.C., Sykes, A., Maybeno, M*., et al.* (2015). RSV-specific airway resident
memory CD8+ T cells and differential disease severity after experimental human
infection. Nat Commun *6*, 10224.
Kim, T.S., Hufford, M.M., Sun, J., Fu, Y.X., and Braciale, T.J. (2010). Antigen
persistence and the control of local T cell memory by migrant respiratory dendritic
cells after acute virus infection. J Exp Med *207*, 1161-1172.
Kory, P., and Kanne, J.P. (2020). SARS-CoV-2 organising pneumonia: 'Has there
been a widespread failure to identify and treat this prevalent condition in COVID-19?'.
BMJ Open Respir Res *7*.
Laing, A.G., Lorenc, A., Del Molino Del Barrio, I., Das, A., Fish, M., Monin, L., Munoz-
Ruiz, M., McKenzie, D.R., Hayday, T.S., Francos-Quijorna, I*., et al.* (2020). A
dynamic COVID-19 immune signature includes associations with poor prognosis. Nat
Med *26*, 1623-1635.
Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted
correlation network analysis. BMC Bioinformatics *9*, 559.
Lee, J., Park, H.K., Kwon, M.J., Ham, S.Y., Kim, J.M., Lim, S.Y., and Song, J.U.
(2020). Decreased lung function is associated with elevated ferritin but not iron or
transferrin saturation in 42,927 healthy Korean men: A cross-sectional study. PLoS
One *15*, e0231057.
Li, Y., Zhang, Z., Yang, L., Lian, X., Xie, Y., Li, S., Xin, S., Cao, P., and Lu, J. (2020).
The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2
Spike. iScience *23*, 101400.
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X.,
Wang, F*., et al.* (2020). Single-cell landscape of bronchoalveolar immune cells in
patients with COVID-19. Nat Med *26*, 842-844.
Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson,
M.K., Mao, T., Oh, J.E., Israelow, B*., et al.* (2020). Longitudinal analyses reveal
immunological misfiring in severe COVID-19. Nature *584*, 463-469.
Mandal, S., Barnett, J., Brill, S.E., Brown, J.S., Denneny, E.K., Hare, S.S.,
Heightman, M., Hillman, T.E., Jacob, J., Jarvis, H.C*., et al.* (2021). 'Long-COVID': a

cross-sectional study of persisting symptoms, biomarker and imaging abnormalities
following hospitalisation for COVID-19. Thorax *76*, 396-398.
Mann, E.R., Menon, M., Knight, S.B., Konkel, J.E., Jagger, C., Shaw, T.N., Krishnan,
S., Rattray, M., Ustianowski, A., Bakerly, N.D*., et al.* (2020). Longitudinal immune
profiling reveals key myeloid signatures associated with COVID-19. Sci Immunol *5*.
Morimoto, Y., Hirahara, K., Kiuchi, M., Wada, T., Ichikawa, T., Kanno, T., Okano, M.,
Kokubo, K., Onodera, A., Sakurai, D*., et al.* (2018). Amphiregulin-Producing
Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and
Facilitate Airway Fibrosis. Immunity *49*, 134-150 e136.
Myall, K.J., Mukherjee, B., Castanheira, A.M., Lam, J.L., Benedetti, G., Mak, S.M.,
Preston, R., Thillai, M., Dewar, A., Molyneaux, P.L., and West, A.G. (2021).
Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of
Corticosteroid Treatment. Ann Am Thorac Soc *18*, 799-806.
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M.V., McGroder, C., Stevens, J.S.,
Cook, J.R., Nordvig, A.S., Shalev, D., Sehrawat, T.S*., et al.* (2021). Post-acute
COVID-19 syndrome. Nat Med *27*, 601-615.
Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Muller, M.A., Dijkman, R., Muth, D.,
Demmers, J.A., Zaki, A., Fouchier, R.A*., et al.* (2013). Dipeptidyl peptidase 4 is a
functional receptor for the emerging human coronavirus-EMC. Nature *495*, 251-254.
Rodriguez, L., Pekkarinen, P.T., Lakshmikanth, T., Tan, Z., Consiglio, C.R., Pou, C.,
Chen, Y., Mugabo, C.H., Nguyen, N.A., Nowlan, K*., et al.* (2020). Systems-Level
Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. Cell Rep
Med *1*, 100078.
Ruan, Q., Yang, K., Wang, W., Jiang, L., and Song, J. (2020). Clinical predictors of
mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan,
China. Intensive Care Med *46*, 846-848.
Saris, A., Reijnders, T.D.Y., Nossent, E.J., Schuurman, A.R., Verhoeff, J., Asten,
S.V., Bontkes, H., Blok, S., Duitman, J., Bogaard, H.J*., et al.* (2021). Distinct cellular
immune profiles in the airways and blood of critically ill patients with COVID-19.
Thorax.
Schmidt, M.E., and Varga, S.M. (2018). The CD8 T Cell Response to Respiratory
Virus Infections. Front Immunol *9*, 678.
Scott, N.A., Knight, S.B., Pearmain, L., Brand, O., Morgan, D.J., Jagger, C., Khan,
S., Hackney, P., Smith, L., Menon, M*., et al.* (2020). Recovery of monocyte
exhaustion is associated with resolution of lung injury in COVID-19 convalescence.
medRxiv, 2020.2010.2010.20207449.
Sigfrid, L., Drake, T.M., Pauley, E., Jesudason, E.C., Olliaro, P., Lim, W.S., Gillesen,
A., Berry, C., Lowe, D.J., McPeake, J*., et al.* (2021). Long Covid in adults discharged
from UK hospitals after Covid-19: A prospective, multicentre cohort study using the
ISARIC WHO Clinical Characterisation Protocol. medRxiv,
2021.2003.2018.21253888.
Slutter, B., Pewe, L.L., Kaech, S.M., and Harty, J.T. (2013). Lung airway-surveilling
CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A
virus. Immunity *39*, 939-948.
Slutter, B., Van Braeckel-Budimir, N., Abboud, G., Varga, S.M., Salek-Ardakani, S.,
and Harty, J.T. (2017). Dynamics of influenza-induced lung-resident memory T cells
underlie waning heterosubtypic immunity. Sci Immunol *2*.
Striz, I., Wang, Y.M., Svarcova, I., Trnka, L., Sorg, C., and Costabel, U. (1993). The
phenotype of alveolar macrophages and its correlation with immune cells in
bronchoalveolar lavage. Eur Respir J *6*, 1287-1294.
Szabo, P.A., Dogra, P., Gray, J.I., Wells, S.B., Connors, T.J., Weisberg, S.P.,
Krupska, I., Matsumoto, R., Poon, M.M.L., Idzikowski, E*., et al.* (2021). Longitudinal
profiling of respiratory and systemic immune responses reveals myeloid cell-driven
lung inflammation in severe COVID-19. Immunity *54*, 797-814 e796.

Szabo, P.A., Miron, M., and Farber, D.L. (2019). Location, location, location: Tissue
resident memory T cells in mice and humans. Sci Immunol *4*.
Thwaites, R.S., Sanchez Sevilla Uruchurtu, A., Siggins, M.K., Liew, F., Russell, C.D.,
Moore, S.C., Fairfield, C., Carter, E., Abrams, S., Short, C.E.*, et al.* (2021).
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-
CSF in severe COVID-19. Sci Immunol *6*.
Wang, E.Y., Mao, T., Klein, J., Dai, Y., Huck, J.D., Liu, F., Zheng, N.S., Zhou, T.,
Israelow, B., Wong, P.*, et al.* (2020). Diverse Functional Autoantibodies in Patients
with COVID-19. medRxiv, 2020.2012.2010.20247205.
Wichmann, D., Sperhake, J.P., Lutgehetmann, M., Steurer, S., Edler, C., Heinemann,
A., Heinrich, F., Mushumba, H., Kniep, I., Schroder, A.S.*, et al.* (2020). Autopsy
Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective
Cohort Study. Ann Intern Med *173*, 268-277.
Wu, T., Hu, Y., Lee, Y.T., Bouchard, K.R., Benechet, A., Khanna, K., and Cauley,
L.S. (2014). Lung-resident memory CD8 T cells (TRM) are indispensable for optimal
cross-protection against pulmonary virus infection. J Leukoc Biol *95*, 215-224.
Yamashita, C.M., Dolgonos, L., Zemans, R.L., Young, S.K., Robertson, J., Briones,
N., Suzuki, T., Campbell, M.N., Gauldie, J., Radisky, D.C.*, et al.* (2011). Matrix
metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol *179*, 1733-1745.
Zhang, B., and Horvath, S. (2005). A general framework for weighted gene co-
expression network analysis. Stat Appl Genet Mol Biol *4*, Article17.
1209

Figure 1: Altered immune cell profile in post-COVID19 BAL over 80 days post discharge

(A) Schematic of study design. BAL and blood were sampled from healthy donors and at > 80 days after hospital discharge from post-COVID19 patients. Traditional and spectral flow cytometry and Olink proteomics was performed on BAL and plasma and correlated with clinical parameters. **(B)** Left: Total number of cells in BAL from healthy controls and post-COVID19 patients. Right: total number of cells in BAL from post-COVID19 patients, stratified according to severity of the acute illness. **(C)** Total cell numbers of immune populations (x10^6/ml) in BAL from healthy controls and post-COVID19 patients, based on gating shown in Methods Figure 1.

Data are presented as mean ± SEM. Healthy controls n = 16, post-COVID19 patients n = 21, moderate n = 6, severe n = 8, very severe n = 7. Statistical significance was tested by Mann Whitney U test or Kruskal Wallis test + Dunn's multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.

Figure 2: A distinct proteome is present in the post COVID-19 airway

436 proteins in BAL and plasma 435 proteins were measured using Olink immunoassays in post-COVID19 patients (n = 19) and healthy controls (n = 9). **(A)** Principal component analysis (PCA) of BAL and plasma proteomes: each point represents a sample. **(B)** Left: heatmap displaying Z-score normalised protein abundance for the 22 proteins that were significantly differentially abundant (5% FDR) between post-COVID19 and healthy controls in BAL. Samples have been ordered by case control status and then by peak severity during acute COVID-19 infection. Proteins are ordered by hierarchical clustering. Right: heatmap for these same 22 proteins in plasma, presented in the same order as for BAL. **(C)** Volcano plot showing differentially protein abundance analysis between post-COVID19 patients and healthy controls in BAL. Nominal $-\log_{10}$ P values are shown. Significantly differentially abundant proteins (5% FDR) are coloured in red and labelled. **(D)** BAL and plasma normalised protein abundance (NPX) expression for the 5 most significantly differentially abundance proteins between post-COVID19 patients and healthy controls. P_{BH} = Benjamini-Hochberg adjusted p-values. **(E)** Correlation between the 22 differentially abundant proteins and immune cell frequency in BAL.

A

Module	Correlation	p_val	p_fdr	p_bonferroni
red	0.53	0.00	0.03	0.03
blue	0.50	0.01	0.03	0.07
black	0.38	0.04	0.11	0.40
turquoise	0.38	0.05	0.11	0.43
brown	0.34	0.08	0.15	0.73
yellow	0.28	0.16	0.22	1.00
grey	-0.26	0.17	0.22	1.00
pink	0.03	0.86	0.91	1.00
green	-0.02	0.91	0.91	1.00

B

C

Red module

Hub Proteins:
CASP3
EPCAM
F3
MB

Figure 3: A network of proteins linked to immune cell chemotaxis and cell death is upregulated in the BAL post-COVID19

WGCNA of BAL proteome of post-COVID19 patients and healthy controls. **(A)** Associations of protein modules identified by WGCNA with case-control status (post-COVID19 or healthy). **(B)** Heatmap displaying Z-score normalised protein abundance for the 37 proteins that form the 'red' protein module. Samples are ordered according to clinical status. Severity refers to peak severity of the acute COVID19 episode. Proteins are ordered by hierarchical clustering. **(C)** Right: Network representation of proteins in the red module and their interconnections defined using String-db. An edge in the network represents a relationship between proteins, coloured according to the type of evidence for the connection (see Methods). Left: list of hub proteins within the network (with hub proteins that were also significantly differentially upregulated in post-COVID19 patient BAL highlighted in red).

Figure 4. CXCR3 ligands and markers of epithelial damage correlate with CD8 T cells in the airways

BAL immune cells and protein concentrations were analysed post-COVID19 infection. **(A)** Linear regression analysis was conducted between n = 435 proteins measured in the BAL using the Olink platform and BAL immune cell frequencies identified by flow cytometry as shown in Figure 1. A heatmap showing proteins with the highest correlation versus 5 major immune cell frequencies is shown. **(B-C)** For each sample, protein levels for CXCL9, -10 and -11, were normalised to the median level in healthy controls. For each sample, the mean of the normalised values for the 3 proteins was calculated to provide a summary metric for CXCR3 chemokines. This was then plotted against versus **(B)** T, NK and NKT proportions in post-COVID19 patients and healthy controls and **(C)** monocyte frequencies and subsets in post-COVID19 patients only. **(D)** BAL T cell frequency versus CD4 and CD8a concentrations as measured by Olink. **(E)** CD8a concentration versus CASP3, EPCAM, MB and DPP4 in the airways. **(F)** DPP4, albumin and LDH concentrations in the BAL determined by ELISA. Data are presented as median ± IQR. **(A)** Pearsons correlation of n = 19 post-COVID19 patients, the r value is shown. **(B-E)** Each point represents an individual patient, linear regression line +/- 95% confidence intervals are depicted, and r and p values from Pearsons correlation are stated. **(F)** represents n = 38 post-COVID19 and n = 20 healthy control individuals. Statistics were conducted using Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001. pCOVID = post-COVID19.

Figure 5. Myeloid cell frequencies are not linked to indications of ongoing damage in the post-COVID19 airway

BAL and blood immune cells from post-COVID19 patients were analyzed by spectral deconvolution cytometry. **(A)** Heatmap of normalised median expression of myeloid cell modulatory and subset markers by clusters of myeloid cells in the airways identified by FlowSOM analysis. **(B)** Violin plot showing frequencies of each cluster in BAL and blood. **(C)** Violin plots showing classical, non-classical and intermediate monocyte subsets as proportions of live leukocytes in BAL and blood identified by manual gating. **(D)** Violin plots showing pDC, cDC1 and cDC2 cell proportions in BAL and blood. **(E)** Geometric mean fluorescence intensity of activation markers expressed by CD11c+ monocytes. **(F)** Pearson's correlation between BAL myeloid subsets (as a % of leukocytes) and airway LDH, albumin and DPP4. Data are presented as median ± IQR. Each point represents an individual patient. Statistical significance for **(B), (C)** and **(D)** was tested by Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.

Figure 6. The airways of post-COVID19 patients are enriched for activated CD8 TRM cells

BAL and blood immune cells from post-COVID19 patients were analyzed by spectral deconvolution cytometry.**(A)** Heatmap of normalised median expression of T cell modulatory and subset markers by clusters of T cells in the airways identified by FlowSOM analysis. **(B)** Violin plot showing frequencies of each cluster in BAL and blood. **(C)** tSNE projection of clusters identified by FlowSOM analysis in BAL and blood. **(D)** Violin plots showing CD4+ and CD8+ T cell subsets as proportions of all T cells in BAL and blood identified by manual gating. **(E)** Violin plots showing gd, NK, NKT and MAIT cell proportions in BAL and blood. **(F)** Pearson correlations between total airway CD4+ and CD8+ T cell numbers and subsets. **(G)** Heatmap depicting Pearson correlation between different T cell populations (as a % of BAL leukocytes) and the concentration of DPP4, LDH and Albumin in the airways. **(F)** Pearson correlations between the gMFI of LDH and albumin. Data are presented as median ± IQR. Each point represents an individual patient. **(A, B, E** and **F)** represent n = 20 individuals. (**C**) represents an equal number of cells from n = 10 patients combined. (**G & H**) represents n = 18 individuals. Statistical significance for **(B), (D), (E)** and **(G)** was tested by Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.

Figure 7. Reduced cellularity in the airways one year after initial bronchoscopy post-COVID19
(A) Total cell counts (left) and proportions of lymphocytes (right) in the BAL following first bronchoscopy and one year follow-up bronchoscopy. **(B)** Cell counts of lymphocyte populations in the BAL following first bronchoscopy and one year follow-up bronchoscopy. **(C)** Cell counts of myeloid populations in the BAL following first bronchoscopy and one year follow-up bronchoscopy. **(D)** Proportions of T cell subsets in the BAL following first bronchoscopy and one year follow-up bronchoscopy. **(E)** LDH (left) and albumin (right) measurements in BAL following first year bronchoscopy and one year follow-up bronchoscopy. **(F)** Percentage of abnormal CT following first year CT and one year follow-up CT. **(G)** BAL LDH and albumin quantification following first year bronchoscopy and one year follow-up bronchoscopy. Each point represents a single patient. Green shading indicates median+/-IQR for proportions of populations and mediator levels observed in healthy airways.